175 results
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
to the Separation and commencing on July 2016, Mr. Espinoza served in a variety of finance leadership roles at Ligand, including Senior Vice President
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Business combination disclosure
8:00am
and 2 approved products Scientific leadership in antibody discovery, genetic engineering, biology / ion channels and systems engineering 76 employees … ‒ Margin expansion ‒ Accretive M&A to enhance scale and capabilities ‒ Creative financings
12 EXPERIENCED LEADERSHIP TEAM & BOARD Carolyn Bertozzi
8-K
EX-99.1
8a292
21 Jun 22
Regulation FD Disclosure
6:19am
425
EX-99.2
cbg 36cmy12yz96k
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.1
2ljez075rsedqzw104
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.3
dnxc77h7s67b
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
i1lk8p7
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
62u9h1
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
0wgb0tq3fz 9upp72
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
9qbbe6hzy
20 Oct 20
Results of Operations and Financial Condition
10:52am